Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Abstract Background: Immune checkpoint inhibitors (ICIs) can lead to one of the common
and quite serious immune-related adverse events (irAEs) in a real-world setting, namely …

Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for
advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly …

Background Current evidence suggests that C-reactive protein (CRP) levels may affect
cancer prognosis. However, the effect of CRP has not been validated in immunotherapy …

Abstract Background and Objective Checkpoint inhibitor-related pneumonitis (CIP) is one of
the most common serious and fatal adverse events associated with immune checkpoint …

Aim With increasing use of immune checkpoint inhibitors (ICIs) more patients will develop
severe and potentially life-threatening immune-related adverse events (irAEs). So far …

Simple Summary Immune checkpoint inhibitors offer the chance for the durable disease
control of advanced/metastatic non-small-cell lung cancer (NSCLC). However, they come …

Introduction: Immune checkpoint inhibitors (ICIs) are a major breakthrough in cancer
treatment. Their increasingly frequent use leads to an uprising incidence of immune-related …

Recently, immune checkpoint inhibitors (ICIs) present promising application prospects in
treating non-small cell lung cancer (NSCLC). This study aimed to investigate optimal …

Background Currently, there is a lack of affordable and accessible indicators that can
accurately predict immune-related adverse events (irAEs) resulting from the use of immune …